|
Rice Bran Supplementation for Radiation-Induced Oral Mucositis in Head and Neck Cancer
RECRUITINGN/ASponsored by Christina Milad Lobos
Actively Recruiting
PhaseN/A
SponsorChristina Milad Lobos
Started2023-01-15
Est. completion2025-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07242859
Summary
This study aims to find out if taking rice bran supplements can help reduce the painful mouth sores (oral mucositis) that often occur in patients with head and neck cancer who receive radiation therapy. The trial will include adult patients undergoing radiation treatment. Participants will be given rice bran supplements during their therapy to see if it can lessen these side effects and improve their overall quality of life.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Male or female patients of age 18 years old tor more * Patients with squamous cell carcinomas without metastases of other non-head and non-neck tumors. * Patients undergoing radiotherapy with an ECOG performance status of 0, 1, or 2 * Patients who will receive IMRT delivered as radical or adjuvant therapy with or without concurrent chemotherapy * Ready to provide written informed consent Exclusion Criteria: * Receiving any other approved or investigational anti-cancer agent than those specified in this study. * Pregnant or breastfeeding female patients * Patients who have oral lesions unrelated to treatment or cancer, * Patients who are on drugs that could cause oral lesions or are using anticoagulants.
Conditions4
CancerHead &Amp; Neck CancerHead &Amp; Neck Squamous Cell CarcinomaRadiation-induced Oral Mucositis
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorChristina Milad Lobos
Started2023-01-15
Est. completion2025-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07242859